We are dedicated to advancing ulviprubart, our investigational product candidate, a potential first in class treatment for people living with #InclusionBodyMyositis, a devastating, chronic disease that impacts daily activities. We believe ulviprubart, an anti-KLRG1 antibody, currently in clinical trials, represents a novel approach to selective depletion of the highly cytotoxic T cells that attack the muscles of those living with #IBM. Learn more about our science, pipeline and clinical trials: https://lnkd.in/eqETNKPs #MyositisAwarenessMonth #Biotech #Autoimmune #IBM
Great to see this pioneering approach advancing. A hope for many patients who are without any treatment option after a long diagnostic journey.
As someone in the ABC008 Trial, I have high hopes and pray it helps. Thank you for what you do, there are thousands of people hoping and praying this works. God Bless this effort, this team and their families.
Thank you for your efforts to help those of us with IBM. Forever grateful for your continued work.
Retired at Jeanne Y Foster , Lic RE Broker Florida
5moThank you for all you do for all of us with IBM. Should you have a vacancy in the ongoing trial please keep me in mind. I'm willing and able to travel anywhere in the USA to participate!